Pfizer's Weight Loss Pill Canceled Due to Serious Side Effects

Pfizer has announced the discontinuation of clinical trials for its weight loss pill, danuglipron, due to high rates of gastrointestinal side effects experienced by patients. The pill, which uses a similar mechanism to semaglutide, resulted in adverse events such as nausea, vomiting, and diarrhea in a large percentage of participants. Despite this setback, Pfizer remains committed to developing a weight loss pill and will continue to explore potential improvements in tolerability and study design. The news of the side effects caused a four percent drop in Pfizer's stock.